Brokerages forecast that Eyenovia Inc (NASDAQ:EYEN) will post ($0.41) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Eyenovia’s earnings. The highest EPS estimate is ($0.34) and the lowest is ($0.48). Eyenovia posted earnings of ($0.43) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 4.7%. The company is scheduled to issue its next quarterly earnings report on Tuesday, November 12th.
On average, analysts expect that Eyenovia will report full-year earnings of ($1.73) per share for the current fiscal year, with EPS estimates ranging from ($2.00) to ($1.55). For the next year, analysts forecast that the company will post earnings of ($1.33) per share, with EPS estimates ranging from ($1.77) to ($1.05). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Eyenovia.
Eyenovia (NASDAQ:EYEN) last issued its earnings results on Monday, August 12th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.03.
Shares of EYEN stock traded down $0.06 on Friday, reaching $3.14. 2,094 shares of the company’s stock traded hands, compared to its average volume of 74,493. Eyenovia has a 12-month low of $2.40 and a 12-month high of $6.98. The company has a market capitalization of $52.12 million, a P/E ratio of -1.73 and a beta of 1.11. The business’s 50 day moving average price is $3.28 and its two-hundred day moving average price is $4.84.
In other news, Director Curt H. Labelle acquired 17,985 shares of Eyenovia stock in a transaction that occurred on Thursday, July 11th. The stock was purchased at an average price of $2.78 per share, with a total value of $49,998.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Tsontcho Ianchulev acquired 233,813 shares of Eyenovia stock in a transaction that occurred on Thursday, July 11th. The shares were purchased at an average cost of $2.78 per share, with a total value of $650,000.14. The disclosure for this purchase can be found here. 43.10% of the stock is currently owned by company insiders.
Large investors have recently made changes to their positions in the business. Bank of New York Mellon Corp acquired a new stake in shares of Eyenovia in the fourth quarter worth about $36,000. Vanguard Group Inc. lifted its stake in shares of Eyenovia by 72.4% in the 2nd quarter. Vanguard Group Inc. now owns 139,748 shares of the company’s stock valued at $601,000 after purchasing an additional 58,697 shares during the period. Finally, Uniplan Investment Counsel Inc. lifted its stake in shares of Eyenovia by 22.4% in the 2nd quarter. Uniplan Investment Counsel Inc. now owns 544,896 shares of the company’s stock valued at $2,343,000 after purchasing an additional 99,896 shares during the period. 8.08% of the stock is owned by institutional investors.
Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.
Featured Story: What does a neutral rating on stocks mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eyenovia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyenovia and related companies with MarketBeat.com's FREE daily email newsletter.